Bysanti

Overview

milsaperidone

atypical antipsychotic

• CYP2D6 substrate
• CYP3A4 substrate
• CNS depression
• decreases central histamine effects
• dopamine antagonist
• extrapyramidal effects
• hyperglycemic effects
• hyperprolactinemic effects
• hyperthermia
• hypotensive effects
• lowers seizure threshold
• prolongs QT interval (conditional)

Contraindicated

• pimozide
Bysanti (milsaperidone)

+

pimozide

1 interaction

Contraindicated

milsaperidone + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia (additive effects)

• quinidine (CYP2D6 inhibitor)
Bysanti (milsaperidone)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Contraindicated

milsaperidone + quinidine (CYP2D6 inhibitor)

contraindicated: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• thioridazine
Bysanti (milsaperidone)

+

thioridazine

1 interaction

Contraindicated

milsaperidone + thioridazine

contraindicated: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

Avoid/Use Alternative

• adagrasib
Bysanti (milsaperidone)

+

adagrasib

1 interaction

Avoid/Use Alternative

milsaperidone + adagrasib

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• aldesleukin
Bysanti (milsaperidone)

+

aldesleukin

1 interaction

Avoid/Use Alternative

milsaperidone + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, seizures, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• alfuzosin
Bysanti (milsaperidone)

+

alfuzosin

1 interaction

Avoid/Use Alternative

milsaperidone + alfuzosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amifampridine
Bysanti (milsaperidone)

+

amifampridine

1 interaction

Avoid/Use Alternative

milsaperidone + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amiodarone
Bysanti (milsaperidone)

+

amiodarone

1 interaction

Avoid/Use Alternative

milsaperidone + amiodarone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anagrelide
Bysanti (milsaperidone)

+

anagrelide

1 interaction

Avoid/Use Alternative

milsaperidone + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Bysanti (milsaperidone)

+

apalutamide

1 interaction

Avoid/Use Alternative

milsaperidone + apalutamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Bysanti (milsaperidone)

+

apomorphine

1 interaction

Avoid/Use Alternative

milsaperidone + apomorphine

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• aripiprazole bimonthly injection
Bysanti (milsaperidone)

+

aripiprazole bimonthly injection

1 interaction

Avoid/Use Alternative

milsaperidone + aripiprazole bimonthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole lauroxil
Bysanti (milsaperidone)

+

aripiprazole lauroxil

1 interaction

Avoid/Use Alternative

milsaperidone + aripiprazole lauroxil

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole monthly injection
Bysanti (milsaperidone)

+

aripiprazole monthly injection

1 interaction

Avoid/Use Alternative

milsaperidone + aripiprazole monthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole oral
Bysanti (milsaperidone)

+

aripiprazole oral

1 interaction

Avoid/Use Alternative

milsaperidone + aripiprazole oral

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• arsenic trioxide
Bysanti (milsaperidone)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

milsaperidone + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Bysanti (milsaperidone)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

milsaperidone + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Bysanti (milsaperidone)

+

asenapine

1 interaction

Avoid/Use Alternative

milsaperidone + asenapine

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• azithromycin
Bysanti (milsaperidone)

+

azithromycin

1 interaction

Avoid/Use Alternative

milsaperidone + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Bysanti (milsaperidone)

+

bedaquiline

1 interaction

Avoid/Use Alternative

milsaperidone + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• benztropine
Bysanti (milsaperidone)

+

benztropine

1 interaction

Avoid/Use Alternative

milsaperidone + benztropine

consider alternative: combo may incr. risk of hyperthermia, including life-threatening (additive effects)

• brexpiprazole
Bysanti (milsaperidone)

+

brexpiprazole

1 interaction

Avoid/Use Alternative

milsaperidone + brexpiprazole

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• bromocriptine
Bysanti (milsaperidone)

+

bromocriptine

1 interaction

Avoid/Use Alternative

milsaperidone + bromocriptine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• butalbital
Bysanti (milsaperidone)

+

butalbital

1 interaction

Avoid/Use Alternative

milsaperidone + butalbital

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• cabergoline
Bysanti (milsaperidone)

+

cabergoline

1 interaction

Avoid/Use Alternative

milsaperidone + cabergoline

use alternative: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• cabozantinib
Bysanti (milsaperidone)

+

cabozantinib

1 interaction

Avoid/Use Alternative

milsaperidone + cabozantinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cariprazine
Bysanti (milsaperidone)

+

cariprazine

1 interaction

Avoid/Use Alternative

milsaperidone + cariprazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• ceritinib
Bysanti (milsaperidone)

+

ceritinib

1 interaction

Avoid/Use Alternative

milsaperidone + ceritinib

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloroquine
Bysanti (milsaperidone)

+

chloroquine

1 interaction

Avoid/Use Alternative

milsaperidone + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, extrapyramidal symptoms (additive effects)

• cisapride
Bysanti (milsaperidone)

+

cisapride

1 interaction

Avoid/Use Alternative

milsaperidone + cisapride

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• citalopram
Bysanti (milsaperidone)

+

citalopram

1 interaction

Avoid/Use Alternative

milsaperidone + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• clarithromycin
Bysanti (milsaperidone)

+

clarithromycin

1 interaction

Avoid/Use Alternative

milsaperidone + clarithromycin

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clofazimine
Bysanti (milsaperidone)

+

clofazimine

1 interaction

Avoid/Use Alternative

milsaperidone + clofazimine

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clonidine
Bysanti (milsaperidone)

+

clonidine

1 interaction

Avoid/Use Alternative

milsaperidone + clonidine

if ADHD use, avoid combo; otherwise, monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• clozapine
Bysanti (milsaperidone)

+

clozapine

1 interaction

Avoid/Use Alternative

milsaperidone + clozapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, seizures, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• codeine
Bysanti (milsaperidone)

+

codeine

1 interaction

Avoid/Use Alternative

milsaperidone + codeine

avoid combo if antitussive use; otherwise, monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• crizotinib
Bysanti (milsaperidone)

+

crizotinib

1 interaction

Avoid/Use Alternative

milsaperidone + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• degarelix
Bysanti (milsaperidone)

+

degarelix

1 interaction

Avoid/Use Alternative

milsaperidone + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Bysanti (milsaperidone)

+

desflurane

1 interaction

Avoid/Use Alternative

milsaperidone + desflurane

use alternative or monitor ECG, BP, respiratory rate, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• desipramine
Bysanti (milsaperidone)

+

desipramine

1 interaction

Avoid/Use Alternative

milsaperidone + desipramine

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine
Bysanti (milsaperidone)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

milsaperidone + dexmedetomidine

use alternative or monitor BP, HR, ECG, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine injection
Bysanti (milsaperidone)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

milsaperidone + dexmedetomidine injection

use alternative or monitor ECG, BP, respiratory rate, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• disopyramide
Bysanti (milsaperidone)

+

disopyramide

1 interaction

Avoid/Use Alternative

milsaperidone + disopyramide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyperthermia (additive effects)

• dofetilide
Bysanti (milsaperidone)

+

dofetilide

1 interaction

Avoid/Use Alternative

milsaperidone + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Bysanti (milsaperidone)

+

domperidone

1 interaction

Avoid/Use Alternative

milsaperidone + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• donepezil
Bysanti (milsaperidone)

+

donepezil

1 interaction

Avoid/Use Alternative

milsaperidone + donepezil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Bysanti (milsaperidone)

+

dordaviprone

1 interaction

Avoid/Use Alternative

milsaperidone + dordaviprone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxazosin
Bysanti (milsaperidone)

+

doxazosin

1 interaction

Avoid/Use Alternative

milsaperidone + doxazosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• doxylamine
Bysanti (milsaperidone)

+

doxylamine

1 interaction

Avoid/Use Alternative

milsaperidone + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• dronedarone
Bysanti (milsaperidone)

+

dronedarone

1 interaction

Avoid/Use Alternative

milsaperidone + dronedarone

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• droperidol
Bysanti (milsaperidone)

+

droperidol

1 interaction

Avoid/Use Alternative

milsaperidone + droperidol

use alternative or monitor ECG, electrolytes; decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• encorafenib
Bysanti (milsaperidone)

+

encorafenib

1 interaction

Avoid/Use Alternative

milsaperidone + encorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ephedra
Bysanti (milsaperidone)

+

ephedra

1 interaction

Avoid/Use Alternative

milsaperidone + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Bysanti (milsaperidone)

+

epirubicin

1 interaction

Avoid/Use Alternative

milsaperidone + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Bysanti (milsaperidone)

+

eribulin

1 interaction

Avoid/Use Alternative

milsaperidone + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Bysanti (milsaperidone)

+

erythromycin

1 interaction

Avoid/Use Alternative

milsaperidone + erythromycin

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ethanol (alcoholic beverage)
Bysanti (milsaperidone)

+

ethanol (alcoholic beverage)

1 interaction

Avoid/Use Alternative

milsaperidone + ethanol (alcoholic beverage)

avoid combo: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ethanol injection
Bysanti (milsaperidone)

+

ethanol injection

1 interaction

Avoid/Use Alternative

milsaperidone + ethanol injection

use alternative or monitor respiratory rate, BP: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• fexinidazole
Bysanti (milsaperidone)

+

fexinidazole

1 interaction

Avoid/Use Alternative

milsaperidone + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after milsaperidone D/C; use alternative or monitor ECG, electrolytes during and x7 days after fexinidazole use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Bysanti (milsaperidone)

+

flecainide

1 interaction

Avoid/Use Alternative

milsaperidone + flecainide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Bysanti (milsaperidone)

+

fluorouracil

1 interaction

Avoid/Use Alternative

milsaperidone + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosfomycin injection
Bysanti (milsaperidone)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

milsaperidone + fosfomycin injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Bysanti (milsaperidone)

+

gilteritinib

1 interaction

Avoid/Use Alternative

milsaperidone + gilteritinib

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• glasdegib
Bysanti (milsaperidone)

+

glasdegib

1 interaction

Avoid/Use Alternative

milsaperidone + glasdegib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Bysanti (milsaperidone)

+

goserelin

1 interaction

Avoid/Use Alternative

milsaperidone + goserelin

PROSTATE CANCER: use alternative or monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. goserelin efficacy (additive effects, androgen deprivation may prolong QT; milsaperidone may cause hyperprolactinemia, decreased GnRH receptors)

• haloperidol
Bysanti (milsaperidone)

+

haloperidol

1 interaction

Avoid/Use Alternative

milsaperidone + haloperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects)

• hydrocodone
Bysanti (milsaperidone)

+

hydrocodone

1 interaction

Avoid/Use Alternative

milsaperidone + hydrocodone

avoid combo if antitussive use; otherwise, monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• hydroxychloroquine
Bysanti (milsaperidone)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

milsaperidone + hydroxychloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• hydroxyzine
Bysanti (milsaperidone)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

milsaperidone + hydroxyzine

use alternative or monitor ECG, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ibutilide
Bysanti (milsaperidone)

+

ibutilide

1 interaction

Avoid/Use Alternative

milsaperidone + ibutilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iloperidone
Bysanti (milsaperidone)

+

iloperidone

1 interaction

Avoid/Use Alternative

milsaperidone + iloperidone

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• inotuzumab ozogamicin
Bysanti (milsaperidone)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

milsaperidone + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isocarboxazid
Bysanti (milsaperidone)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

milsaperidone + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• isoflurane
Bysanti (milsaperidone)

+

isoflurane

1 interaction

Avoid/Use Alternative

milsaperidone + isoflurane

use alternative or monitor BP, ECG, respiratory rate, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• ivosidenib
Bysanti (milsaperidone)

+

ivosidenib

1 interaction

Avoid/Use Alternative

milsaperidone + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• kava
Bysanti (milsaperidone)

+

kava

1 interaction

Avoid/Use Alternative

milsaperidone + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• kratom
Bysanti (milsaperidone)

+

kratom

1 interaction

Avoid/Use Alternative

milsaperidone + kratom

use alternative or monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• lefamulin
Bysanti (milsaperidone)

+

lefamulin

1 interaction

Avoid/Use Alternative

milsaperidone + lefamulin

use alternative or monitor ECG, electrolytes: combo with oral lefamulin may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo with IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• leuprolide
Bysanti (milsaperidone)

+

leuprolide

1 interaction

Avoid/Use Alternative

milsaperidone + leuprolide

PROSTATE CANCER: use alternative or monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; milsaperidone may cause hyperprolactinemia, decreased GnRH receptors)

• levofloxacin
Bysanti (milsaperidone)

+

levofloxacin

1 interaction

Avoid/Use Alternative

milsaperidone + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Bysanti (milsaperidone)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

milsaperidone + levoketoconazole

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lofexidine
Bysanti (milsaperidone)

+

lofexidine

1 interaction

Avoid/Use Alternative

milsaperidone + lofexidine

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• lonafarnib
Bysanti (milsaperidone)

+

lonafarnib

1 interaction

Avoid/Use Alternative

milsaperidone + lonafarnib

use alternative or monitor HR, ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lumateperone
Bysanti (milsaperidone)

+

lumateperone

1 interaction

Avoid/Use Alternative

milsaperidone + lumateperone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• lurasidone
Bysanti (milsaperidone)

+

lurasidone

1 interaction

Avoid/Use Alternative

milsaperidone + lurasidone

use alternative or monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• macimorelin
Bysanti (milsaperidone)

+

macimorelin

1 interaction

Avoid/Use Alternative

milsaperidone + macimorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• metaxalone
Bysanti (milsaperidone)

+

metaxalone

1 interaction

Avoid/Use Alternative

milsaperidone + metaxalone

use alternative or monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• methadone
Bysanti (milsaperidone)

+

methadone

1 interaction

Avoid/Use Alternative

milsaperidone + methadone

use alternative or monitor ECG, electrolytes, BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• metoclopramide
Bysanti (milsaperidone)

+

metoclopramide

1 interaction

Avoid/Use Alternative

milsaperidone + metoclopramide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• midazolam
Bysanti (milsaperidone)

+

midazolam

1 interaction

Avoid/Use Alternative

milsaperidone + midazolam

use alternative or monitor BP, respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• mobocertinib
Bysanti (milsaperidone)

+

mobocertinib

1 interaction

Avoid/Use Alternative

milsaperidone + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• moxifloxacin
Bysanti (milsaperidone)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

milsaperidone + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• netupitant
Bysanti (milsaperidone)

+

netupitant

1 interaction

Avoid/Use Alternative

milsaperidone + netupitant

use alternative or monitor ECG; consider decr. milsaperidone dose during and x1wk after (fos)netupitant use: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nilotinib
Bysanti (milsaperidone)

+

nilotinib

1 interaction

Avoid/Use Alternative

milsaperidone + nilotinib

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• olanzapine
Bysanti (milsaperidone)

+

olanzapine

1 interaction

Avoid/Use Alternative

milsaperidone + olanzapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• oliceridine
Bysanti (milsaperidone)

+

oliceridine

1 interaction

Avoid/Use Alternative

milsaperidone + oliceridine

use alternative or monitor ECG, electrolytes, BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ondansetron
Bysanti (milsaperidone)

+

ondansetron

1 interaction

Avoid/Use Alternative

milsaperidone + ondansetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Bysanti (milsaperidone)

+

osimertinib

1 interaction

Avoid/Use Alternative

milsaperidone + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxybate
Bysanti (milsaperidone)

+

oxybate

1 interaction

Avoid/Use Alternative

milsaperidone + oxybate

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

• pacritinib
Bysanti (milsaperidone)

+

pacritinib

1 interaction

Avoid/Use Alternative

milsaperidone + pacritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paliperidone
Bysanti (milsaperidone)

+

paliperidone

1 interaction

Avoid/Use Alternative

milsaperidone + paliperidone

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• palonosetron
Bysanti (milsaperidone)

+

palonosetron

1 interaction

Avoid/Use Alternative

milsaperidone + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Bysanti (milsaperidone)

+

pasireotide

1 interaction

Avoid/Use Alternative

milsaperidone + pasireotide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentamidine
Bysanti (milsaperidone)

+

pentamidine

1 interaction

Avoid/Use Alternative

milsaperidone + pentamidine

use alternative or monitor ECG, BP, electrolytes; risk may be lower with nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• phenelzine
Bysanti (milsaperidone)

+

phenelzine

1 interaction

Avoid/Use Alternative

milsaperidone + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• phenoxybenzamine
Bysanti (milsaperidone)

+

phenoxybenzamine

1 interaction

Avoid/Use Alternative

milsaperidone + phenoxybenzamine

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• phentolamine
Bysanti (milsaperidone)

+

phentolamine

1 interaction

Avoid/Use Alternative

milsaperidone + phentolamine

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pitolisant
Bysanti (milsaperidone)

+

pitolisant

1 interaction

Avoid/Use Alternative

milsaperidone + pitolisant

avoid combo: combo may decr. pitolisant efficacy (antagonistic effects)

• prazosin
Bysanti (milsaperidone)

+

prazosin

1 interaction

Avoid/Use Alternative

milsaperidone + prazosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• procainamide
Bysanti (milsaperidone)

+

procainamide

1 interaction

Avoid/Use Alternative

milsaperidone + procainamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Bysanti (milsaperidone)

+

promethazine

1 interaction

Avoid/Use Alternative

milsaperidone + promethazine

use alternative or monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, seizures, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• propafenone
Bysanti (milsaperidone)

+

propafenone

1 interaction

Avoid/Use Alternative

milsaperidone + propafenone

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• quetiapine
Bysanti (milsaperidone)

+

quetiapine

1 interaction

Avoid/Use Alternative

milsaperidone + quetiapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• quinidine (antiarrhythmic)
Bysanti (milsaperidone)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

milsaperidone + quinidine (antiarrhythmic)

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quinine
Bysanti (milsaperidone)

+

quinine

1 interaction

Avoid/Use Alternative

milsaperidone + quinine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Bysanti (milsaperidone)

+

quizartinib

1 interaction

Avoid/Use Alternative

milsaperidone + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rasagiline
Bysanti (milsaperidone)

+

rasagiline

1 interaction

Avoid/Use Alternative

milsaperidone + rasagiline

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• revumenib
Bysanti (milsaperidone)

+

revumenib

1 interaction

Avoid/Use Alternative

milsaperidone + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Bysanti (milsaperidone)

+

ribociclib

1 interaction

Avoid/Use Alternative

milsaperidone + ribociclib

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• risperidone
Bysanti (milsaperidone)

+

risperidone

1 interaction

Avoid/Use Alternative

milsaperidone + risperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• romidepsin
Bysanti (milsaperidone)

+

romidepsin

1 interaction

Avoid/Use Alternative

milsaperidone + romidepsin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropeginterferon alfa-2b
Bysanti (milsaperidone)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

milsaperidone + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rucaparib
Bysanti (milsaperidone)

+

rucaparib

1 interaction

Avoid/Use Alternative

milsaperidone + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• safinamide
Bysanti (milsaperidone)

+

safinamide

1 interaction

Avoid/Use Alternative

milsaperidone + safinamide

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• scopolamine
Bysanti (milsaperidone)

+

scopolamine

1 interaction

Avoid/Use Alternative

milsaperidone + scopolamine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, including life-threatening (additive effects)

• selegiline
Bysanti (milsaperidone)

+

selegiline

1 interaction

Avoid/Use Alternative

milsaperidone + selegiline

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• selegiline transdermal
Bysanti (milsaperidone)

+

selegiline transdermal

1 interaction

Avoid/Use Alternative

milsaperidone + selegiline transdermal

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• selpercatinib
Bysanti (milsaperidone)

+

selpercatinib

1 interaction

Avoid/Use Alternative

milsaperidone + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sevoflurane
Bysanti (milsaperidone)

+

sevoflurane

1 interaction

Avoid/Use Alternative

milsaperidone + sevoflurane

use alternative or monitor BP, ECG, electrolytes, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• silodosin
Bysanti (milsaperidone)

+

silodosin

1 interaction

Avoid/Use Alternative

milsaperidone + silodosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sotalol
Bysanti (milsaperidone)

+

sotalol

1 interaction

Avoid/Use Alternative

milsaperidone + sotalol

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• taletrectinib
Bysanti (milsaperidone)

+

taletrectinib

1 interaction

Avoid/Use Alternative

milsaperidone + taletrectinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tamsulosin
Bysanti (milsaperidone)

+

tamsulosin

1 interaction

Avoid/Use Alternative

milsaperidone + tamsulosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• telavancin
Bysanti (milsaperidone)

+

telavancin

1 interaction

Avoid/Use Alternative

milsaperidone + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• terazosin
Bysanti (milsaperidone)

+

terazosin

1 interaction

Avoid/Use Alternative

milsaperidone + terazosin

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tetrabenazine
Bysanti (milsaperidone)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

milsaperidone + tetrabenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• thalidomide
Bysanti (milsaperidone)

+

thalidomide

1 interaction

Avoid/Use Alternative

milsaperidone + thalidomide

use alternative or monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• toremifene
Bysanti (milsaperidone)

+

toremifene

1 interaction

Avoid/Use Alternative

milsaperidone + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tradipitant
Bysanti (milsaperidone)

+

tradipitant

1 interaction

Avoid/Use Alternative

milsaperidone + tradipitant

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tramadol
Bysanti (milsaperidone)

+

tramadol

1 interaction

Avoid/Use Alternative

milsaperidone + tramadol

use alternative or monitor ECG, electrolytes, BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, seizures, severe hypotension, including orthostasis, syncope (additive effects)

• tranylcypromine
Bysanti (milsaperidone)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

milsaperidone + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• triclabendazole
Bysanti (milsaperidone)

+

triclabendazole

1 interaction

Avoid/Use Alternative

milsaperidone + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Bysanti (milsaperidone)

+

trifluridine

1 interaction

Avoid/Use Alternative

milsaperidone + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethobenzamide
Bysanti (milsaperidone)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

milsaperidone + trimethobenzamide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• triptorelin
Bysanti (milsaperidone)

+

triptorelin

1 interaction

Avoid/Use Alternative

milsaperidone + triptorelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. triptorelin efficacy (additive effects, androgen deprivation may prolong QT; milsaperidone may cause hyperprolactinemia, decreased GnRH receptors)

• vandetanib
Bysanti (milsaperidone)

+

vandetanib

1 interaction

Avoid/Use Alternative

milsaperidone + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Bysanti (milsaperidone)

+

vemurafenib

1 interaction

Avoid/Use Alternative

milsaperidone + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• yohimbe
Bysanti (milsaperidone)

+

yohimbe

1 interaction

Avoid/Use Alternative

milsaperidone + yohimbe

avoid combo: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ziftomenib
Bysanti (milsaperidone)

+

ziftomenib

1 interaction

Avoid/Use Alternative

milsaperidone + ziftomenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Bysanti (milsaperidone)

+

ziprasidone

1 interaction

Avoid/Use Alternative

milsaperidone + ziprasidone

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• zuranolone
Bysanti (milsaperidone)

+

zuranolone

1 interaction

Avoid/Use Alternative

milsaperidone + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• abiraterone acetate
Bysanti (milsaperidone)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

milsaperidone + abiraterone acetate

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• acarbose
Bysanti (milsaperidone)

+

acarbose

1 interaction

Monitor/Modify Tx

milsaperidone + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acebutolol
Bysanti (milsaperidone)

+

acebutolol

1 interaction

Monitor/Modify Tx

milsaperidone + acebutolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• alfentanil
Bysanti (milsaperidone)

+

alfentanil

1 interaction

Monitor/Modify Tx

milsaperidone + alfentanil

monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• aliskiren
Bysanti (milsaperidone)

+

aliskiren

1 interaction

Monitor/Modify Tx

milsaperidone + aliskiren

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• alogliptin
Bysanti (milsaperidone)

+

alogliptin

1 interaction

Monitor/Modify Tx

milsaperidone + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• alprazolam
Bysanti (milsaperidone)

+

alprazolam

1 interaction

Monitor/Modify Tx

milsaperidone + alprazolam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• alprostadil intracavernous
Bysanti (milsaperidone)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

milsaperidone + alprostadil intracavernous

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amantadine
Bysanti (milsaperidone)

+

amantadine

1 interaction

Monitor/Modify Tx

milsaperidone + amantadine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amifostine
Bysanti (milsaperidone)

+

amifostine

1 interaction

Monitor/Modify Tx

milsaperidone + amifostine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• amiloride
Bysanti (milsaperidone)

+

amiloride

1 interaction

Monitor/Modify Tx

milsaperidone + amiloride

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amitriptyline
Bysanti (milsaperidone)

+

amitriptyline

1 interaction

Monitor/Modify Tx

milsaperidone + amitriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amlodipine
Bysanti (milsaperidone)

+

amlodipine

1 interaction

Monitor/Modify Tx

milsaperidone + amlodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amoxapine
Bysanti (milsaperidone)

+

amoxapine

1 interaction

Monitor/Modify Tx

milsaperidone + amoxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• apraclonidine ophthalmic
Bysanti (milsaperidone)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + apraclonidine ophthalmic

monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• aprepitant
Bysanti (milsaperidone)

+

aprepitant

1 interaction

Monitor/Modify Tx

milsaperidone + aprepitant

if aprepitant 3-day regimen, monitor ECG; aprepitant single dose-regimen OK: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• aprocitentan
Bysanti (milsaperidone)

+

aprocitentan

1 interaction

Monitor/Modify Tx

milsaperidone + aprocitentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• articaine
Bysanti (milsaperidone)

+

articaine

1 interaction

Monitor/Modify Tx

milsaperidone + articaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• atazanavir
Bysanti (milsaperidone)

+

atazanavir

1 interaction

Monitor/Modify Tx

milsaperidone + atazanavir

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• atenolol
Bysanti (milsaperidone)

+

atenolol

1 interaction

Monitor/Modify Tx

milsaperidone + atenolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• avacopan
Bysanti (milsaperidone)

+

avacopan

1 interaction

Monitor/Modify Tx

milsaperidone + avacopan

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• avanafil
Bysanti (milsaperidone)

+

avanafil

1 interaction

Monitor/Modify Tx

milsaperidone + avanafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• azilsartan medoxomil
Bysanti (milsaperidone)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

milsaperidone + azilsartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• baclofen intrathecal
Bysanti (milsaperidone)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

milsaperidone + baclofen intrathecal

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• benazepril
Bysanti (milsaperidone)

+

benazepril

1 interaction

Monitor/Modify Tx

milsaperidone + benazepril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• berberine
Bysanti (milsaperidone)

+

berberine

1 interaction

Monitor/Modify Tx

milsaperidone + berberine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• berotralstat
Bysanti (milsaperidone)

+

berotralstat

1 interaction

Monitor/Modify Tx

milsaperidone + berotralstat

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• betaxolol
Bysanti (milsaperidone)

+

betaxolol

1 interaction

Monitor/Modify Tx

milsaperidone + betaxolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• betaxolol ophthalmic
Bysanti (milsaperidone)

+

betaxolol ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + betaxolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bethanechol
Bysanti (milsaperidone)

+

bethanechol

1 interaction

Monitor/Modify Tx

milsaperidone + bethanechol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bexagliflozin
Bysanti (milsaperidone)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + bexagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bisoprolol
Bysanti (milsaperidone)

+

bisoprolol

1 interaction

Monitor/Modify Tx

milsaperidone + bisoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bortezomib
Bysanti (milsaperidone)

+

bortezomib

1 interaction

Monitor/Modify Tx

milsaperidone + bortezomib

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• brimonidine ophthalmic
Bysanti (milsaperidone)

+

brimonidine ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + brimonidine ophthalmic

monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• brimonidine topical
Bysanti (milsaperidone)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

milsaperidone + brimonidine topical

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• bumetanide
Bysanti (milsaperidone)

+

bumetanide

1 interaction

Monitor/Modify Tx

milsaperidone + bumetanide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine
Bysanti (milsaperidone)

+

bupivacaine

1 interaction

Monitor/Modify Tx

milsaperidone + bupivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine liposomal
Bysanti (milsaperidone)

+

bupivacaine liposomal

1 interaction

Monitor/Modify Tx

milsaperidone + bupivacaine liposomal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• buprenorphine
Bysanti (milsaperidone)

+

buprenorphine

1 interaction

Monitor/Modify Tx

milsaperidone + buprenorphine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• bupropion
Bysanti (milsaperidone)

+

bupropion

1 interaction

Monitor/Modify Tx

milsaperidone + bupropion

monitor ECG; decr. milsaperidone maintenance dose 50%, consider lower bupropion doses: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• butorphanol
Bysanti (milsaperidone)

+

butorphanol

1 interaction

Monitor/Modify Tx

milsaperidone + butorphanol

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• canagliflozin
Bysanti (milsaperidone)

+

canagliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + canagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• candesartan cilexetil
Bysanti (milsaperidone)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

milsaperidone + candesartan cilexetil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cannabis
Bysanti (milsaperidone)

+

cannabis

1 interaction

Monitor/Modify Tx

milsaperidone + cannabis

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• capivasertib
Bysanti (milsaperidone)

+

capivasertib

1 interaction

Monitor/Modify Tx

milsaperidone + capivasertib

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• captopril
Bysanti (milsaperidone)

+

captopril

1 interaction

Monitor/Modify Tx

milsaperidone + captopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carbamazepine
Bysanti (milsaperidone)

+

carbamazepine

1 interaction

Monitor/Modify Tx

milsaperidone + carbamazepine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including syncope; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• carteolol ophthalmic
Bysanti (milsaperidone)

+

carteolol ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + carteolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carvedilol
Bysanti (milsaperidone)

+

carvedilol

1 interaction

Monitor/Modify Tx

milsaperidone + carvedilol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chloramphenicol
Bysanti (milsaperidone)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

milsaperidone + chloramphenicol

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• chlordiazepoxide
Bysanti (milsaperidone)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

milsaperidone + chlordiazepoxide

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• chloroprocaine
Bysanti (milsaperidone)

+

chloroprocaine

1 interaction

Monitor/Modify Tx

milsaperidone + chloroprocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorothiazide
Bysanti (milsaperidone)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

milsaperidone + chlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorpromazine
Bysanti (milsaperidone)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

milsaperidone + chlorpromazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• chlorthalidone
Bysanti (milsaperidone)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

milsaperidone + chlorthalidone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cilostazol
Bysanti (milsaperidone)

+

cilostazol

1 interaction

Monitor/Modify Tx

milsaperidone + cilostazol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cinacalcet
Bysanti (milsaperidone)

+

cinacalcet

1 interaction

Monitor/Modify Tx

milsaperidone + cinacalcet

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Bysanti (milsaperidone)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

milsaperidone + ciprofloxacin

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• clevidipine
Bysanti (milsaperidone)

+

clevidipine

1 interaction

Monitor/Modify Tx

milsaperidone + clevidipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• clobazam
Bysanti (milsaperidone)

+

clobazam

1 interaction

Monitor/Modify Tx

milsaperidone + clobazam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• clofarabine
Bysanti (milsaperidone)

+

clofarabine

1 interaction

Monitor/Modify Tx

milsaperidone + clofarabine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• clomipramine
Bysanti (milsaperidone)

+

clomipramine

1 interaction

Monitor/Modify Tx

milsaperidone + clomipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, seizures, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• clonazepam
Bysanti (milsaperidone)

+

clonazepam

1 interaction

Monitor/Modify Tx

milsaperidone + clonazepam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• clorazepate
Bysanti (milsaperidone)

+

clorazepate

1 interaction

Monitor/Modify Tx

milsaperidone + clorazepate

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• cobicistat
Bysanti (milsaperidone)

+

cobicistat

1 interaction

Monitor/Modify Tx

milsaperidone + cobicistat

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• coenzyme Q-10
Bysanti (milsaperidone)

+

coenzyme Q-10

1 interaction

Monitor/Modify Tx

milsaperidone + coenzyme Q-10

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• colesevelam
Bysanti (milsaperidone)

+

colesevelam

1 interaction

Monitor/Modify Tx

milsaperidone + colesevelam

monitor glucose in type 2 diabetes mellitus patients: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• conivaptan
Bysanti (milsaperidone)

+

conivaptan

1 interaction

Monitor/Modify Tx

milsaperidone + conivaptan

monitor ECG during and x7 days after conivaptan use: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• cyclosporine
Bysanti (milsaperidone)

+

cyclosporine

1 interaction

Monitor/Modify Tx

milsaperidone + cyclosporine

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dacomitinib
Bysanti (milsaperidone)

+

dacomitinib

1 interaction

Monitor/Modify Tx

milsaperidone + dacomitinib

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• danazol
Bysanti (milsaperidone)

+

danazol

1 interaction

Monitor/Modify Tx

milsaperidone + danazol

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dapagliflozin
Bysanti (milsaperidone)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + dapagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• daridorexant
Bysanti (milsaperidone)

+

daridorexant

1 interaction

Monitor/Modify Tx

milsaperidone + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darunavir
Bysanti (milsaperidone)

+

darunavir

1 interaction

Monitor/Modify Tx

milsaperidone + darunavir

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• denileukin diftitox
Bysanti (milsaperidone)

+

denileukin diftitox

1 interaction

Monitor/Modify Tx

milsaperidone + denileukin diftitox

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• diazepam
Bysanti (milsaperidone)

+

diazepam

1 interaction

Monitor/Modify Tx

milsaperidone + diazepam

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• dihydrocodeine
Bysanti (milsaperidone)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

milsaperidone + dihydrocodeine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• diltiazem
Bysanti (milsaperidone)

+

diltiazem

1 interaction

Monitor/Modify Tx

milsaperidone + diltiazem

monitor ECG, BP: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• dinutuximab
Bysanti (milsaperidone)

+

dinutuximab

1 interaction

Monitor/Modify Tx

milsaperidone + dinutuximab

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• dipyridamole
Bysanti (milsaperidone)

+

dipyridamole

1 interaction

Monitor/Modify Tx

milsaperidone + dipyridamole

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• doxepin
Bysanti (milsaperidone)

+

doxepin

1 interaction

Monitor/Modify Tx

milsaperidone + doxepin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• dronabinol
Bysanti (milsaperidone)

+

dronabinol

1 interaction

Monitor/Modify Tx

milsaperidone + dronabinol

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dulaglutide
Bysanti (milsaperidone)

+

dulaglutide

1 interaction

Monitor/Modify Tx

milsaperidone + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duloxetine
Bysanti (milsaperidone)

+

duloxetine

1 interaction

Monitor/Modify Tx

milsaperidone + duloxetine

monitor ECG, BP: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• duvelisib
Bysanti (milsaperidone)

+

duvelisib

1 interaction

Monitor/Modify Tx

milsaperidone + duvelisib

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• eliglustat
Bysanti (milsaperidone)

+

eliglustat

1 interaction

Monitor/Modify Tx

milsaperidone + eliglustat

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• empagliflozin
Bysanti (milsaperidone)

+

empagliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + empagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• enalapril
Bysanti (milsaperidone)

+

enalapril

1 interaction

Monitor/Modify Tx

milsaperidone + enalapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• enalaprilat
Bysanti (milsaperidone)

+

enalaprilat

1 interaction

Monitor/Modify Tx

milsaperidone + enalaprilat

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• entacapone
Bysanti (milsaperidone)

+

entacapone

1 interaction

Monitor/Modify Tx

milsaperidone + entacapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• entrectinib
Bysanti (milsaperidone)

+

entrectinib

1 interaction

Monitor/Modify Tx

milsaperidone + entrectinib

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• eplerenone
Bysanti (milsaperidone)

+

eplerenone

1 interaction

Monitor/Modify Tx

milsaperidone + eplerenone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• epoprostenol
Bysanti (milsaperidone)

+

epoprostenol

1 interaction

Monitor/Modify Tx

milsaperidone + epoprostenol

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• ertugliflozin
Bysanti (milsaperidone)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + ertugliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• esketamine
Bysanti (milsaperidone)

+

esketamine

1 interaction

Monitor/Modify Tx

milsaperidone + esketamine

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• esmolol
Bysanti (milsaperidone)

+

esmolol

1 interaction

Monitor/Modify Tx

milsaperidone + esmolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• estazolam
Bysanti (milsaperidone)

+

estazolam

1 interaction

Monitor/Modify Tx

milsaperidone + estazolam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• eszopiclone
Bysanti (milsaperidone)

+

eszopiclone

1 interaction

Monitor/Modify Tx

milsaperidone + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethacrynic acid
Bysanti (milsaperidone)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

milsaperidone + ethacrynic acid

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ethanol (in some formulations)
Bysanti (milsaperidone)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

milsaperidone + ethanol (in some formulations)

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etomidate
Bysanti (milsaperidone)

+

etomidate

1 interaction

Monitor/Modify Tx

milsaperidone + etomidate

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etripamil nasal
Bysanti (milsaperidone)

+

etripamil nasal

1 interaction

Monitor/Modify Tx

milsaperidone + etripamil nasal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• exenatide
Bysanti (milsaperidone)

+

exenatide

1 interaction

Monitor/Modify Tx

milsaperidone + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fedratinib
Bysanti (milsaperidone)

+

fedratinib

1 interaction

Monitor/Modify Tx

milsaperidone + fedratinib

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• felodipine
Bysanti (milsaperidone)

+

felodipine

1 interaction

Monitor/Modify Tx

milsaperidone + felodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• fenoldopam
Bysanti (milsaperidone)

+

fenoldopam

1 interaction

Monitor/Modify Tx

milsaperidone + fenoldopam

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• fentanyl
Bysanti (milsaperidone)

+

fentanyl

1 interaction

Monitor/Modify Tx

milsaperidone + fentanyl

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ferumoxytol
Bysanti (milsaperidone)

+

ferumoxytol

1 interaction

Monitor/Modify Tx

milsaperidone + ferumoxytol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• flaxseed
Bysanti (milsaperidone)

+

flaxseed

1 interaction

Monitor/Modify Tx

milsaperidone + flaxseed

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• flibanserin
Bysanti (milsaperidone)

+

flibanserin

1 interaction

Monitor/Modify Tx

milsaperidone + flibanserin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• fluconazole
Bysanti (milsaperidone)

+

fluconazole

1 interaction

Monitor/Modify Tx

milsaperidone + fluconazole

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• fluoxetine
Bysanti (milsaperidone)

+

fluoxetine

1 interaction

Monitor/Modify Tx

milsaperidone + fluoxetine

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluphenazine
Bysanti (milsaperidone)

+

fluphenazine

1 interaction

Monitor/Modify Tx

milsaperidone + fluphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• flurazepam
Bysanti (milsaperidone)

+

flurazepam

1 interaction

Monitor/Modify Tx

milsaperidone + flurazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• fosamprenavir
Bysanti (milsaperidone)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

milsaperidone + fosamprenavir

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• fosinopril
Bysanti (milsaperidone)

+

fosinopril

1 interaction

Monitor/Modify Tx

milsaperidone + fosinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• foslevodopa
Bysanti (milsaperidone)

+

foslevodopa

1 interaction

Monitor/Modify Tx

milsaperidone + foslevodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• furosemide
Bysanti (milsaperidone)

+

furosemide

1 interaction

Monitor/Modify Tx

milsaperidone + furosemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• gabapentin
Bysanti (milsaperidone)

+

gabapentin

1 interaction

Monitor/Modify Tx

milsaperidone + gabapentin

monitor respiratory rate; consider decr. gabapentin dose: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• gabapentin enacarbil
Bysanti (milsaperidone)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

milsaperidone + gabapentin enacarbil

monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• garlic
Bysanti (milsaperidone)

+

garlic

1 interaction

Monitor/Modify Tx

milsaperidone + garlic

monitor BP with supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• givosiran
Bysanti (milsaperidone)

+

givosiran

1 interaction

Monitor/Modify Tx

milsaperidone + givosiran

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited; givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glimepiride
Bysanti (milsaperidone)

+

glimepiride

1 interaction

Monitor/Modify Tx

milsaperidone + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Bysanti (milsaperidone)

+

glipizide

1 interaction

Monitor/Modify Tx

milsaperidone + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Bysanti (milsaperidone)

+

glyburide

1 interaction

Monitor/Modify Tx

milsaperidone + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• grapefruit
Bysanti (milsaperidone)

+

grapefruit

1 interaction

Monitor/Modify Tx

milsaperidone + grapefruit

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited)

• guanfacine
Bysanti (milsaperidone)

+

guanfacine

1 interaction

Monitor/Modify Tx

milsaperidone + guanfacine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• histrelin
Bysanti (milsaperidone)

+

histrelin

1 interaction

Monitor/Modify Tx

milsaperidone + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. histrelin efficacy (additive effects, androgen deprivation may prolong QT; milsaperidone may cause hyperprolactinemia, decreased GnRH receptors)

• hydralazine
Bysanti (milsaperidone)

+

hydralazine

1 interaction

Monitor/Modify Tx

milsaperidone + hydralazine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydrochlorothiazide
Bysanti (milsaperidone)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

milsaperidone + hydrochlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydromorphone
Bysanti (milsaperidone)

+

hydromorphone

1 interaction

Monitor/Modify Tx

milsaperidone + hydromorphone

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• idelalisib
Bysanti (milsaperidone)

+

idelalisib

1 interaction

Monitor/Modify Tx

milsaperidone + idelalisib

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ifosfamide
Bysanti (milsaperidone)

+

ifosfamide

1 interaction

Monitor/Modify Tx

milsaperidone + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloprost
Bysanti (milsaperidone)

+

iloprost

1 interaction

Monitor/Modify Tx

milsaperidone + iloprost

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• imatinib
Bysanti (milsaperidone)

+

imatinib

1 interaction

Monitor/Modify Tx

milsaperidone + imatinib

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• imipramine
Bysanti (milsaperidone)

+

imipramine

1 interaction

Monitor/Modify Tx

milsaperidone + imipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• indapamide
Bysanti (milsaperidone)

+

indapamide

1 interaction

Monitor/Modify Tx

milsaperidone + indapamide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• insulin
Bysanti (milsaperidone)

+

insulin

1 interaction

Monitor/Modify Tx

milsaperidone + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• iohexol
Bysanti (milsaperidone)

+

iohexol

1 interaction

Monitor/Modify Tx

milsaperidone + iohexol

if intrathecal iohexol use, D/C milsaperidone at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Bysanti (milsaperidone)

+

iopamidol

1 interaction

Monitor/Modify Tx

milsaperidone + iopamidol

caution advised if intrathecal iopamidol use; consider holding milsaperidone at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Bysanti (milsaperidone)

+

irbesartan

1 interaction

Monitor/Modify Tx

milsaperidone + irbesartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• iron sucrose
Bysanti (milsaperidone)

+

iron sucrose

1 interaction

Monitor/Modify Tx

milsaperidone + iron sucrose

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• isavuconazonium
Bysanti (milsaperidone)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

milsaperidone + isavuconazonium

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• isosorbide dinitrate
Bysanti (milsaperidone)

+

isosorbide dinitrate

1 interaction

Monitor/Modify Tx

milsaperidone + isosorbide dinitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isosorbide mononitrate
Bysanti (milsaperidone)

+

isosorbide mononitrate

1 interaction

Monitor/Modify Tx

milsaperidone + isosorbide mononitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isradipine
Bysanti (milsaperidone)

+

isradipine

1 interaction

Monitor/Modify Tx

milsaperidone + isradipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• itraconazole
Bysanti (milsaperidone)

+

itraconazole

1 interaction

Monitor/Modify Tx

milsaperidone + itraconazole

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ketamine
Bysanti (milsaperidone)

+

ketamine

1 interaction

Monitor/Modify Tx

milsaperidone + ketamine

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• ketoconazole
Bysanti (milsaperidone)

+

ketoconazole

1 interaction

Monitor/Modify Tx

milsaperidone + ketoconazole

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• labetalol
Bysanti (milsaperidone)

+

labetalol

1 interaction

Monitor/Modify Tx

milsaperidone + labetalol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• landiolol
Bysanti (milsaperidone)

+

landiolol

1 interaction

Monitor/Modify Tx

milsaperidone + landiolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lemborexant
Bysanti (milsaperidone)

+

lemborexant

1 interaction

Monitor/Modify Tx

milsaperidone + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lenacapavir
Bysanti (milsaperidone)

+

lenacapavir

1 interaction

Monitor/Modify Tx

milsaperidone + lenacapavir

monitor ECG during and x9mo after lenacapavir use: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• letermovir
Bysanti (milsaperidone)

+

letermovir

1 interaction

Monitor/Modify Tx

milsaperidone + letermovir

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• levobunolol ophthalmic
Bysanti (milsaperidone)

+

levobunolol ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + levobunolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• levodopa
Bysanti (milsaperidone)

+

levodopa

1 interaction

Monitor/Modify Tx

milsaperidone + levodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• levorphanol
Bysanti (milsaperidone)

+

levorphanol

1 interaction

Monitor/Modify Tx

milsaperidone + levorphanol

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• lidocaine
Bysanti (milsaperidone)

+

lidocaine

1 interaction

Monitor/Modify Tx

milsaperidone + lidocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• linagliptin
Bysanti (milsaperidone)

+

linagliptin

1 interaction

Monitor/Modify Tx

milsaperidone + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Bysanti (milsaperidone)

+

liraglutide

1 interaction

Monitor/Modify Tx

milsaperidone + liraglutide

monitor glucose in type 2 diabetes mellitus patients: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lisinopril
Bysanti (milsaperidone)

+

lisinopril

1 interaction

Monitor/Modify Tx

milsaperidone + lisinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lithium
Bysanti (milsaperidone)

+

lithium

1 interaction

Monitor/Modify Tx

milsaperidone + lithium

D/C one or both drugs if encephalopathy occurs: combo may incr. risk of encephalopathic syndrome, extrapyramidal symptoms (additive effects)

• lixisenatide
Bysanti (milsaperidone)

+

lixisenatide

1 interaction

Monitor/Modify Tx

milsaperidone + lixisenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lopinavir/ritonavir
Bysanti (milsaperidone)

+

lopinavir/ ritonavir

1 interaction

Monitor/Modify Tx

milsaperidone + lopinavir/ ritonavir

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lorazepam
Bysanti (milsaperidone)

+

lorazepam

1 interaction

Monitor/Modify Tx

milsaperidone + lorazepam

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• losartan
Bysanti (milsaperidone)

+

losartan

1 interaction

Monitor/Modify Tx

milsaperidone + losartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• loxapine
Bysanti (milsaperidone)

+

loxapine

1 interaction

Monitor/Modify Tx

milsaperidone + loxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• lubiprostone
Bysanti (milsaperidone)

+

lubiprostone

1 interaction

Monitor/Modify Tx

milsaperidone + lubiprostone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• magnesium sulfate
Bysanti (milsaperidone)

+

magnesium sulfate

1 interaction

Monitor/Modify Tx

milsaperidone + magnesium sulfate

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• maraviroc
Bysanti (milsaperidone)

+

maraviroc

1 interaction

Monitor/Modify Tx

milsaperidone + maraviroc

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• mavorixafor
Bysanti (milsaperidone)

+

mavorixafor

1 interaction

Monitor/Modify Tx

milsaperidone + mavorixafor

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• meperidine
Bysanti (milsaperidone)

+

meperidine

1 interaction

Monitor/Modify Tx

milsaperidone + meperidine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• mepivacaine
Bysanti (milsaperidone)

+

mepivacaine

1 interaction

Monitor/Modify Tx

milsaperidone + mepivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metformin
Bysanti (milsaperidone)

+

metformin

1 interaction

Monitor/Modify Tx

milsaperidone + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• methohexital
Bysanti (milsaperidone)

+

methohexital

1 interaction

Monitor/Modify Tx

milsaperidone + methohexital

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methyldopa
Bysanti (milsaperidone)

+

methyldopa

1 interaction

Monitor/Modify Tx

milsaperidone + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methylene blue injection
Bysanti (milsaperidone)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

milsaperidone + methylene blue injection

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metolazone
Bysanti (milsaperidone)

+

metolazone

1 interaction

Monitor/Modify Tx

milsaperidone + metolazone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metoprolol
Bysanti (milsaperidone)

+

metoprolol

1 interaction

Monitor/Modify Tx

milsaperidone + metoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• mifepristone
Bysanti (milsaperidone)

+

mifepristone

1 interaction

Monitor/Modify Tx

milsaperidone + mifepristone

monitor ECG; decr. milsaperidone maintenance dose 50% during and x14 days after daily mifepristone use: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• miglitol
Bysanti (milsaperidone)

+

miglitol

1 interaction

Monitor/Modify Tx

milsaperidone + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• milrinone
Bysanti (milsaperidone)

+

milrinone

1 interaction

Monitor/Modify Tx

milsaperidone + milrinone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• minoxidil
Bysanti (milsaperidone)

+

minoxidil

1 interaction

Monitor/Modify Tx

milsaperidone + minoxidil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• mirabegron
Bysanti (milsaperidone)

+

mirabegron

1 interaction

Monitor/Modify Tx

milsaperidone + mirabegron

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mirtazapine
Bysanti (milsaperidone)

+

mirtazapine

1 interaction

Monitor/Modify Tx

milsaperidone + mirtazapine

monitor BP; consider decr. dose of one or both drugs: combo may increase risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• moexipril
Bysanti (milsaperidone)

+

moexipril

1 interaction

Monitor/Modify Tx

milsaperidone + moexipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• molindone
Bysanti (milsaperidone)

+

molindone

1 interaction

Monitor/Modify Tx

milsaperidone + molindone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• morphine
Bysanti (milsaperidone)

+

morphine

1 interaction

Monitor/Modify Tx

milsaperidone + morphine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nadolol
Bysanti (milsaperidone)

+

nadolol

1 interaction

Monitor/Modify Tx

milsaperidone + nadolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nalbuphine
Bysanti (milsaperidone)

+

nalbuphine

1 interaction

Monitor/Modify Tx

milsaperidone + nalbuphine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nateglinide
Bysanti (milsaperidone)

+

nateglinide

1 interaction

Monitor/Modify Tx

milsaperidone + nateglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nattokinase
Bysanti (milsaperidone)

+

nattokinase

1 interaction

Monitor/Modify Tx

milsaperidone + nattokinase

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• naxitamab
Bysanti (milsaperidone)

+

naxitamab

1 interaction

Monitor/Modify Tx

milsaperidone + naxitamab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nebivolol
Bysanti (milsaperidone)

+

nebivolol

1 interaction

Monitor/Modify Tx

milsaperidone + nebivolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nefazodone
Bysanti (milsaperidone)

+

nefazodone

1 interaction

Monitor/Modify Tx

milsaperidone + nefazodone

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• nelarabine
Bysanti (milsaperidone)

+

nelarabine

1 interaction

Monitor/Modify Tx

milsaperidone + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelfinavir
Bysanti (milsaperidone)

+

nelfinavir

1 interaction

Monitor/Modify Tx

milsaperidone + nelfinavir

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• niacin (vitamin B3)
Bysanti (milsaperidone)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

milsaperidone + niacin (vitamin B3)

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nicardipine
Bysanti (milsaperidone)

+

nicardipine

1 interaction

Monitor/Modify Tx

milsaperidone + nicardipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nifedipine
Bysanti (milsaperidone)

+

nifedipine

1 interaction

Monitor/Modify Tx

milsaperidone + nifedipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nimodipine
Bysanti (milsaperidone)

+

nimodipine

1 interaction

Monitor/Modify Tx

milsaperidone + nimodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nirogacestat
Bysanti (milsaperidone)

+

nirogacestat

1 interaction

Monitor/Modify Tx

milsaperidone + nirogacestat

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Bysanti (milsaperidone)

+

nisoldipine

1 interaction

Monitor/Modify Tx

milsaperidone + nisoldipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitric oxide
Bysanti (milsaperidone)

+

nitric oxide

1 interaction

Monitor/Modify Tx

milsaperidone + nitric oxide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitrite
Bysanti (milsaperidone)

+

nitrite

1 interaction

Monitor/Modify Tx

milsaperidone + nitrite

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nitroglycerin
Bysanti (milsaperidone)

+

nitroglycerin

1 interaction

Monitor/Modify Tx

milsaperidone + nitroglycerin

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• nitroprusside
Bysanti (milsaperidone)

+

nitroprusside

1 interaction

Monitor/Modify Tx

milsaperidone + nitroprusside

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nortriptyline
Bysanti (milsaperidone)

+

nortriptyline

1 interaction

Monitor/Modify Tx

milsaperidone + nortriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• obinutuzumab
Bysanti (milsaperidone)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

milsaperidone + obinutuzumab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• olmesartan medoxomil
Bysanti (milsaperidone)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

milsaperidone + olmesartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• opicapone
Bysanti (milsaperidone)

+

opicapone

1 interaction

Monitor/Modify Tx

milsaperidone + opicapone

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• opium
Bysanti (milsaperidone)

+

opium

1 interaction

Monitor/Modify Tx

milsaperidone + opium

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxazepam
Bysanti (milsaperidone)

+

oxazepam

1 interaction

Monitor/Modify Tx

milsaperidone + oxazepam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• oxybutynin
Bysanti (milsaperidone)

+

oxybutynin

1 interaction

Monitor/Modify Tx

milsaperidone + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxycodone
Bysanti (milsaperidone)

+

oxycodone

1 interaction

Monitor/Modify Tx

milsaperidone + oxycodone

monitor BP, respiratory rate; decr. oxycodone start dose by at least 50%, consider decr. milsaperidone dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxymorphone
Bysanti (milsaperidone)

+

oxymorphone

1 interaction

Monitor/Modify Tx

milsaperidone + oxymorphone

monitor BP, respiratory rate; decr. oxymorphone start dose by at least 50%, consider decr. milsaperidone dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• palopegteriparatide
Bysanti (milsaperidone)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

milsaperidone + palopegteriparatide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• paroxetine
Bysanti (milsaperidone)

+

paroxetine

1 interaction

Monitor/Modify Tx

milsaperidone + paroxetine

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• pentazocine
Bysanti (milsaperidone)

+

pentazocine

1 interaction

Monitor/Modify Tx

milsaperidone + pentazocine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• pentobarbital
Bysanti (milsaperidone)

+

pentobarbital

1 interaction

Monitor/Modify Tx

milsaperidone + pentobarbital

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• perindopril
Bysanti (milsaperidone)

+

perindopril

1 interaction

Monitor/Modify Tx

milsaperidone + perindopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• perphenazine
Bysanti (milsaperidone)

+

perphenazine

1 interaction

Monitor/Modify Tx

milsaperidone + perphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, severe hypotension, including orthostasis, syncope (additive effects)

• phenobarbital
Bysanti (milsaperidone)

+

phenobarbital

1 interaction

Monitor/Modify Tx

milsaperidone + phenobarbital

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• pindolol
Bysanti (milsaperidone)

+

pindolol

1 interaction

Monitor/Modify Tx

milsaperidone + pindolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pioglitazone
Bysanti (milsaperidone)

+

pioglitazone

1 interaction

Monitor/Modify Tx

milsaperidone + pioglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• posaconazole
Bysanti (milsaperidone)

+

posaconazole

1 interaction

Monitor/Modify Tx

milsaperidone + posaconazole

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pramipexole
Bysanti (milsaperidone)

+

pramipexole

1 interaction

Monitor/Modify Tx

milsaperidone + pramipexole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• pramlintide
Bysanti (milsaperidone)

+

pramlintide

1 interaction

Monitor/Modify Tx

milsaperidone + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• pregabalin
Bysanti (milsaperidone)

+

pregabalin

1 interaction

Monitor/Modify Tx

milsaperidone + pregabalin

monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• primidone
Bysanti (milsaperidone)

+

primidone

1 interaction

Monitor/Modify Tx

milsaperidone + primidone

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

• procarbazine
Bysanti (milsaperidone)

+

procarbazine

1 interaction

Monitor/Modify Tx

milsaperidone + procarbazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• prochlorperazine
Bysanti (milsaperidone)

+

prochlorperazine

1 interaction

Monitor/Modify Tx

milsaperidone + prochlorperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• propofol
Bysanti (milsaperidone)

+

propofol

1 interaction

Monitor/Modify Tx

milsaperidone + propofol

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• propranolol
Bysanti (milsaperidone)

+

propranolol

1 interaction

Monitor/Modify Tx

milsaperidone + propranolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• protriptyline
Bysanti (milsaperidone)

+

protriptyline

1 interaction

Monitor/Modify Tx

milsaperidone + protriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• quazepam
Bysanti (milsaperidone)

+

quazepam

1 interaction

Monitor/Modify Tx

milsaperidone + quazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• quinapril
Bysanti (milsaperidone)

+

quinapril

1 interaction

Monitor/Modify Tx

milsaperidone + quinapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ramipril
Bysanti (milsaperidone)

+

ramipril

1 interaction

Monitor/Modify Tx

milsaperidone + ramipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• remifentanil
Bysanti (milsaperidone)

+

remifentanil

1 interaction

Monitor/Modify Tx

milsaperidone + remifentanil

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• remimazolam
Bysanti (milsaperidone)

+

remimazolam

1 interaction

Monitor/Modify Tx

milsaperidone + remimazolam

monitor BP, respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• repaglinide
Bysanti (milsaperidone)

+

repaglinide

1 interaction

Monitor/Modify Tx

milsaperidone + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rilzabrutinib
Bysanti (milsaperidone)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

milsaperidone + rilzabrutinib

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• riociguat
Bysanti (milsaperidone)

+

riociguat

1 interaction

Monitor/Modify Tx

milsaperidone + riociguat

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• ritonavir
Bysanti (milsaperidone)

+

ritonavir

1 interaction

Monitor/Modify Tx

milsaperidone + ritonavir

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• rolapitant
Bysanti (milsaperidone)

+

rolapitant

1 interaction

Monitor/Modify Tx

milsaperidone + rolapitant

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ropinirole
Bysanti (milsaperidone)

+

ropinirole

1 interaction

Monitor/Modify Tx

milsaperidone + ropinirole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• ropivacaine
Bysanti (milsaperidone)

+

ropivacaine

1 interaction

Monitor/Modify Tx

milsaperidone + ropivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• rosiglitazone
Bysanti (milsaperidone)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

milsaperidone + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rotigotine transdermal
Bysanti (milsaperidone)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

milsaperidone + rotigotine transdermal

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• sacubitril
Bysanti (milsaperidone)

+

sacubitril

1 interaction

Monitor/Modify Tx

milsaperidone + sacubitril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• saxagliptin
Bysanti (milsaperidone)

+

saxagliptin

1 interaction

Monitor/Modify Tx

milsaperidone + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• semaglutide
Bysanti (milsaperidone)

+

semaglutide

1 interaction

Monitor/Modify Tx

milsaperidone + semaglutide

monitor glucose in type 2 diabetes mellitus patients: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sildenafil
Bysanti (milsaperidone)

+

sildenafil

1 interaction

Monitor/Modify Tx

milsaperidone + sildenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sitagliptin
Bysanti (milsaperidone)

+

sitagliptin

1 interaction

Monitor/Modify Tx

milsaperidone + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sodium ferric gluconate complex
Bysanti (milsaperidone)

+

sodium ferric gluconate complex

1 interaction

Monitor/Modify Tx

milsaperidone + sodium ferric gluconate complex

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sotagliflozin
Bysanti (milsaperidone)

+

sotagliflozin

1 interaction

Monitor/Modify Tx

milsaperidone + sotagliflozin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sparsentan
Bysanti (milsaperidone)

+

sparsentan

1 interaction

Monitor/Modify Tx

milsaperidone + sparsentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• spironolactone
Bysanti (milsaperidone)

+

spironolactone

1 interaction

Monitor/Modify Tx

milsaperidone + spironolactone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sufentanil
Bysanti (milsaperidone)

+

sufentanil

1 interaction

Monitor/Modify Tx

milsaperidone + sufentanil

monitor BP, respiratory rate; decr. sufentanil start dose, consider decr. milsaperidone dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• suvorexant
Bysanti (milsaperidone)

+

suvorexant

1 interaction

Monitor/Modify Tx

milsaperidone + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tadalafil
Bysanti (milsaperidone)

+

tadalafil

1 interaction

Monitor/Modify Tx

milsaperidone + tadalafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tagraxofusp
Bysanti (milsaperidone)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

milsaperidone + tagraxofusp

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tapentadol
Bysanti (milsaperidone)

+

tapentadol

1 interaction

Monitor/Modify Tx

milsaperidone + tapentadol

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• taurine
Bysanti (milsaperidone)

+

taurine

1 interaction

Monitor/Modify Tx

milsaperidone + taurine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• telmisartan
Bysanti (milsaperidone)

+

telmisartan

1 interaction

Monitor/Modify Tx

milsaperidone + telmisartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• temazepam
Bysanti (milsaperidone)

+

temazepam

1 interaction

Monitor/Modify Tx

milsaperidone + temazepam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• terbinafine
Bysanti (milsaperidone)

+

terbinafine

1 interaction

Monitor/Modify Tx

milsaperidone + terbinafine

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• thiothixene
Bysanti (milsaperidone)

+

thiothixene

1 interaction

Monitor/Modify Tx

milsaperidone + thiothixene

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• timolol
Bysanti (milsaperidone)

+

timolol

1 interaction

Monitor/Modify Tx

milsaperidone + timolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• timolol ophthalmic
Bysanti (milsaperidone)

+

timolol ophthalmic

1 interaction

Monitor/Modify Tx

milsaperidone + timolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tipranavir
Bysanti (milsaperidone)

+

tipranavir

1 interaction

Monitor/Modify Tx

milsaperidone + tipranavir

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tirzepatide
Bysanti (milsaperidone)

+

tirzepatide

1 interaction

Monitor/Modify Tx

milsaperidone + tirzepatide

monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tizanidine
Bysanti (milsaperidone)

+

tizanidine

1 interaction

Monitor/Modify Tx

milsaperidone + tizanidine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tolcapone
Bysanti (milsaperidone)

+

tolcapone

1 interaction

Monitor/Modify Tx

milsaperidone + tolcapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• torsemide
Bysanti (milsaperidone)

+

torsemide

1 interaction

Monitor/Modify Tx

milsaperidone + torsemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• trandolapril
Bysanti (milsaperidone)

+

trandolapril

1 interaction

Monitor/Modify Tx

milsaperidone + trandolapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• trazodone
Bysanti (milsaperidone)

+

trazodone

1 interaction

Monitor/Modify Tx

milsaperidone + trazodone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• treprostinil
Bysanti (milsaperidone)

+

treprostinil

1 interaction

Monitor/Modify Tx

milsaperidone + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• triamterene
Bysanti (milsaperidone)

+

triamterene

1 interaction

Monitor/Modify Tx

milsaperidone + triamterene

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• triazolam
Bysanti (milsaperidone)

+

triazolam

1 interaction

Monitor/Modify Tx

milsaperidone + triazolam

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• trifluoperazine
Bysanti (milsaperidone)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

milsaperidone + trifluoperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, severe hypotension, including orthostasis, syncope (additive effects)

• trimipramine
Bysanti (milsaperidone)

+

trimipramine

1 interaction

Monitor/Modify Tx

milsaperidone + trimipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• tucatinib
Bysanti (milsaperidone)

+

tucatinib

1 interaction

Monitor/Modify Tx

milsaperidone + tucatinib

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• valsartan
Bysanti (milsaperidone)

+

valsartan

1 interaction

Monitor/Modify Tx

milsaperidone + valsartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• vardenafil
Bysanti (milsaperidone)

+

vardenafil

1 interaction

Monitor/Modify Tx

milsaperidone + vardenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• verapamil
Bysanti (milsaperidone)

+

verapamil

1 interaction

Monitor/Modify Tx

milsaperidone + verapamil

monitor ECG, BP: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• voriconazole
Bysanti (milsaperidone)

+

voriconazole

1 interaction

Monitor/Modify Tx

milsaperidone + voriconazole

monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• vosoritide
Bysanti (milsaperidone)

+

vosoritide

1 interaction

Monitor/Modify Tx

milsaperidone + vosoritide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• zaleplon
Bysanti (milsaperidone)

+

zaleplon

1 interaction

Monitor/Modify Tx

milsaperidone + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Bysanti (milsaperidone)

+

ziconotide

1 interaction

Monitor/Modify Tx

milsaperidone + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Bysanti (milsaperidone)

+

zolpidem

1 interaction

Monitor/Modify Tx

milsaperidone + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)